S*BIO's Oral JAK2 Inhibitor SB1518 Demonstrates Therapeutic Potential for the Treatment of Myeloproliferative and Other Hematological... (57 SB939: A potent and orally-active ...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> MEDICINE >> NEWS

S*BIO's Oral JAK2 Inhibitor SB1518 Demonstrates Therapeutic Potential for the Treatment of Myeloproliferative and Other Hematological Disorders

Date:12/10/2007

SB939: A potent and orally-active HDAC inhibitor for the treatment of hematological malignancies

SB939, a novel histone deacetylase HDAC inhibitor with improved metabolic, pharmacokinetic and pharmacological properties compared to other HDAC inhibitors, is currently in Phase I clinical trials, and has demonstrated potential for the treatment of various types of hematological malignancies.

Poster No. 747

SB1317, a potent and orally-active FLT3-CDK inhibitor with high anti-tumor efficacy in models of hematological malignancies

SB1317, a novel potent inhibitor of FLT3 kinase and CDKs 1, 2 and 9, demonstrated therapeutic potential for the treatment of hematological malignancies. FLT3 is the most common mutated gene in acute myeloid leukemia

(AML), and CDK1, 2, and 9 are well-established anti-cancer targets due to their direct role in cell cycle control.

About S*BIO Pte Ltd

S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, has entered the clinic in 2Q 2007. It recently announced that a second compound, SB1518, would enter the clinic in 1H 2008 and that a third compound, SB1317, is in pre-clinical development.

In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong linkages with a network of medical oncologists in Asia Pacific and its investors include Bio*One Capital, Novartis Bioventures and other international funds. More information about S*BIO can be found at http://www.sbio.com.

S*BIO Pte Ltd:

Stephen Keith Rhind, Ph.D.

Senior Vice President, Cor
'/>"/>

SOURCE S*BIO Pte Ltd
Copyright©2007 PR Newswire.
All rights reserved

5

GOOD

Page: 1 2 3
Related medicine news :

1. Impending FDA Approval Decision on the First HIV Integrase Inhibitor Can Have Significant Impact for Patients
2. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme
3. S*BIO Expands Pipeline With the Development of a Unique Flt3 -CDK Inhibitor as a Targeted Therapy for Acute Leukemias
4. SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor
5. Silencing small but mighty cancer inhibitors
6. Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds
7. Study Demonstrates Marteks Algal DHA Oil Improves Blood Triglyceride Lipid Levels
8. Highmarks Hospital Pay-for-Performance Program Demonstrates Impressive Results
9. Facet Solutions AFRS(TM) Implant Demonstrates Positive Clinical Results After One Year Follow Up
10. LIALDA demonstrates prolonged release of mesalamine in an in vitro study using a simulated colon
11. ENDEAVOR IV achieves primary endpoint, demonstrates similar safety profile compared to Taxus stent

Post Your Comments:

[0] Procter & Gamble Announces Appointment of Director [0] Possible ovarian cancer treatment target identified [0] Testosterone Gets Bad Rap: Study [0] Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries)[0] People living in poorer neighborhoods at increased risk for death, worse health risks

Other Medicine News:Health News:Researchers find medical inpatients with unhealthy alcohol use may benefit from brief intervention 2 Health News:United Physicians, P.C. Selects National City, Now Part of PNC, for Physician Banking Program 2 Health News:Landmark NBC News Nutrition Report: 'There Is Indeed Little Difference Between High Fructose Corn Syrup and Table Sugar' 2 Health News:Harvard Medical School Prostate Disease Website Guides Patients Through Decision-Making Process 2

Ultrasound changes care of some patients with rheumatic conditions Educating physicians about ventilation-perfusion scanning leads to reduced radiation exposure Researchers find medical inpatients with unhealthy alcohol use may benefit from brief intervention United Physicians, P.C. Selects National City, Now Part of PNC, for Physician Banking Program Landmark NBC News Nutrition Report: 'There Is Indeed Little Difference Between High Fructose Corn Syrup and Table Sugar'Harvard Medical School Prostate Disease Website Guides Patients Through Decision-Making Process

Breaking Medicine Technology:Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 2 Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 3 Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 4 Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 5 Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 6 Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 7 Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 8 Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 2 Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 3 Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 4 Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 5 Veran Medical Receives FDA Clearance to Market Electromagnetic Navigated Bronchoscopy Product: The SPiN Drive(TM) System 2 iHealthSpot Inc Named Winner in the 2009 STEVIE 26apos 3B AWARDS 28American Business Awards 29 50003 1 iHealthSpot Inc Named Winner in the 2009 STEVIE 26apos 3B AWARDS 28American Business Awards 29 50003 2 iHealthSpot Inc Named Winner in the 2009 STEVIE 26apos 3B AWARDS 28American Business Awards 29 50003 3 iHealthSpot Inc Named Winner in the 2009 STEVIE 26apos 3B AWARDS 28American Business Awards 29 50003 4 Allsup Outlines Advantages of Representation to Overcome Long Wait for Social Security Disability 50001 1 Allsup Outlines Advantages of Representation to Overcome Long Wait for Social Security Disability 50001 2 Allsup Outlines Advantages of Representation to Overcome Long Wait for Social Security Disability 50001 3 Allsup Outlines Advantages of Representation to Overcome Long Wait for Social Security Disability 50001 4 Allsup Outlines Advantages of Representation to Overcome Long Wait for Social Security Disability 50001 5 Jarrow Formulas Inc to Unveil Children 26apos 3Bs Natural Health Products at Upcoming Natural MarketPlace 2009 Show in Las Vegas 49999 1 Jarrow Formulas Inc to Unveil Children 26apos 3Bs Natural Health Products at Upcoming Natural MarketPlace 2009 Show in Las Vegas 49999 2 Jarrow Formulas Inc to Unveil Children 26apos 3Bs Natural Health Products at Upcoming Natural MarketPlace 2009 Show in Las Vegas 49999 3

[0] Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective [0] Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities [0] Veran Medical Receives FDA Clearance to Market Electromagnetic Navigated Bronchoscopy Product: The SPiN Drive(TM) System

Other Medicine Technology:Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd. 2 Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd. 3 Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 2 Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 3 Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 4 Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 5 Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 6

Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose

Medicine Products:

Topcon Telemedicine System Multi-functional spectral transmittance meter AIT-250W instrument table Topcon MC-3 Chart Projector

S*BIO's Oral JAK2 Inhibitor SB1518 Demonstrates Therapeutic Potential for the Treatment of Myeloproliferative and Other Hematological...(57 SB939: A potent and orally-active ...),Health